Oncology Based In-Vivo CRO Market to Reach $2.69 Billion at 8.41% CAGR as AI and Advanced Tumor Models Reshape Research Outsourcing
Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The global oncology-based in-vivo contract research organization (CRO) market is projected to reach USD 1.65 billion in 2026 and grow at a compound annual growth rate (CAGR) of 8.41% to USD 2.69 billion by 2032. This market research report examines growth drivers, evolving study requirements, technology adoption, regional conditions, and strategic priorities shaping outsourced preclinical oncology research.
Market Scope and Growth Drivers
Oncology-based in-vivo CROs provide animal-model research services that evaluate cancer biology, therapeutic activity, pharmacology, toxicology, and biomarker relationships. Their work informs decisions before clinical testing and requires rigorous study design, animal-welfare oversight, reproducibility, and regulatory alignment.
Market demand is supported by increasingly complex oncology pipelines and the need for specialized models, validated endpoints, and integrated data interpretation. The report provides decision-makers with a practical basis for assessing market opportunities, refining outsourcing strategies, and evaluating the capabilities required for successful preclinical programs.
Model Innovation and Translational Rigor
Outsourced research is shifting from routine efficacy testing toward more translationally relevant study programs. Sponsors increasingly seek scientifically appropriate model systems, including:
Multiparametric readouts, longitudinal monitoring, pharmacokinetic and pharmacodynamic integration, and biomarker evaluation are becoming central to study value. Continued emphasis on replacement, reduction, and refinement also increases the importance of careful model selection and study quality.
Artificial Intelligence in In-Vivo Oncology Research
Artificial intelligence and machine learning can strengthen model prioritization, imaging segmentation, treatment-response analysis, protocol optimization, and anomaly detection. These tools may also support the integration of pathology, molecular, imaging, and pharmacology data.
Effective adoption depends on well-annotated datasets, transparent validation, controlled data pipelines, cybersecurity safeguards, version control, and expert review. AI complements rather than replaces biological judgment, ethical oversight, and appropriately designed experiments.
Regional Market Landscape
Comparisons across major countries and international groups-including ASEAN, BRICS, the European Union, G7, GCC, and NATO members-highlight differences in infrastructure, compliance, data governance, procurement, and research collaboration. These insights support market-entry planning and help organizations anticipate operational risks across jurisdictions.
Strategic Priorities for Sponsors and CROs
Partner selection should reflect demonstrated expertise in the required tumor type, model, endpoint, and therapeutic modality rather than capacity alone. Key considerations include:
The competitive assessment enables leaders to benchmark prospective partners, strengthen study governance, and identify service capabilities that can create a durable advantage.
Key Takeaways from This Report
Key Topics Covered
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oncology Based In-Vivo CRO Market, by Model Type
7.1. Introduction
7.2. Human Tumor Models
7.2.1. CDX
7.2.2. PDX
7.3. Animal Tumor Models
7.3.1. Rodent
7.3.2. Canine
7.3.3. Rabbit
7.3.4. Zebrafish
8. Oncology Based In-Vivo CRO Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Oncology Based In-Vivo CRO Market, by Cancer Indication
9.1. Introduction
9.2. Solid Tumors
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Colorectal Cancer
9.2.4. Pancreatic Cancer
9.2.5. Liver Cancer
9.3. Hematological Cancers
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Multiple Myeloma
9.4. Rare Cancers
9.4.1. Sarcoma
9.4.2. Neuroendocrine Tumors
9.4.3. Pediatric Cancers
10. Oncology Based In-Vivo CRO Market, by Study Duration
10.1. Introduction
10.2. Short-Term Studies
10.3. Long-Term Studies
11. Oncology Based In-Vivo CRO Market, by Therapy
11.1. Introduction
11.2. Chemotherapy
11.3. Immunotherapy
11.3.1. Checkpoint Inhibitors
11.3.2. Cytokine Therapies
11.3.3. Cancer Vaccines
11.4. Targeted Therapy
11.4.1. Kinase Inhibitors
11.4.2. Small Molecule Inhibitors
11.5. Biologics
11.5.1. Monoclonal Antibodies
11.5.2. Antibody-Drug Conjugates (ADCs)
11.6. Cell & Gene Therapies
11.6.1. CAR-T Cell Models
11.6.2. TCR-Engineered Cell Models
11.7. Nanotherapeutics
11.7.1. Polymer-Based Nanoparticles
11.7.2. Liposomal Formulations
12. Oncology Based In-Vivo CRO Market, by End User
12.1. Introduction
12.2. Academia & Research Institute
12.3. Pharmaceutical & Biotechnology Companies
12.4. Government & Public Research Organizations
13. Oncology Based In-Vivo CRO Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Latin America
13.6. Africa
13.7. Middle East
14. Oncology Based In-Vivo CRO Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. BRICS
14.5. European Union
14.6. ASEAN
14.7. GCC
15. Oncology Based In-Vivo CRO Market, by Country
15.1. Introduction
15.2. China
15.3. United States
15.4. Japan
15.5. India
15.6. Germany
15.7. United Kingdom
15.8. Australia
15.9. France
15.10. South Korea
15.11. Canada
15.12. Italy
15.13. Brazil
15.14. Mexico
15.15. Russia
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Charles River Laboratories International, Inc.
17.2. WuXi AppTec Co., Ltd.
17.3. Laboratory Corporation of America Holdings
17.4. ICON plc
17.5. Parexel International Corporation
17.6. Eurofins Scientific S.E.
17.7. Medpace, Inc.
17.8. Pharmaron Beijing Co., Ltd.
17.9. Champions Oncology, Inc
17.10. Syngene International Limited
17.11. Evotec SE
17.12. Crown Bioscience, Inc.
17.13. Novotech Health Holdings
17.14. Aragen Life Sciences Ltd.
17.15. The Jackson Laboratory
17.16. Linical Co., Ltd.
17.17. Experimental Pharmacology & Oncology Berlin-Buch GmbH
17.18. Aurigene Pharmaceutical Services Ltd.
17.19. Noble Life Sciences
17.20. Taconic Biosciences, Inc.
17.21. Melior Discovery Inc.
17.22. Reaction Biology Corporation
17.23. Altogen Labs
17.24. Cellvax, SAS
17.25. Explicyte
17.26. Imavita S.A.S.
17.27. InnoSer
17.28. IVRS AB
17.29. Oncodesign Services
17.30. Pharmatest Services
17.31. The Living Tumor Laboratory
17.32. TheraIndx Lifesciences Pvt. Ltd.
18. Key Experts
LIST OF FIGURES [23]
LIST OF TABLES [347]
For more information about this report visit https://www.researchandmarkets.com/r/3qsgpo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.